Table 2.
Characteristics of mucormycosis and patients’ outcome
| N (%) or Median (IQR) | All n = 26 |
Survivors in ICU n = 6 |
Non survivors in ICU n = 20 |
P value |
|---|---|---|---|---|
| Diagnosisa | 0.12 | |||
| Proven | 14 (54) | 2 (33) | 12 (60) | |
| Probable | 5 (19) | 3 (50) | 2 (10) | |
| Possible with positive qPCR | 7 (27) | 1 (17) | 6 (30) | |
| Involvement | ||||
| Pulmonary | 16 (62) | 4 (67) | 12 (60) | 1.00 |
| Rhino-cerebral | 10 (38) | 3 (50) | 7 (35) | 0.85 |
| Digestive | 5 (19) | 0 | 5 (25) | 0.44 |
| Skin | 2 (8) | 0 | 2 (10) | 1.00 |
| Disseminated | 8 (31) | 1 (17) | 7 (35) | 0.73 |
| Species | 0.45 | |||
| Rhizopus/Mucor | 8 (31) | 3 (50) | 5 (25) | |
| Lichteimia | 3 (12) | 0 | 3 (15) | |
| Rhizomucor | 2 (8) | 0 | 2 (10) | |
| Lichteimia/Rizomucor | 1 (4) | 0 | 1 (5) | |
| Rhizopus | 1 (4) | 0 | 1 (5) | |
| Mucor | 1 (4) | 0 | 1 (5) | |
| Unknown | 10 (38) | 3 (50) | 7 (35) | |
| Concomitant infection | ||||
| Fungal | 8 (31) | 3 (50) | 5 (25) | 1.00 |
| Bacterial | 8 (31) | 2 (33) | 6 (30) | 0.51 |
| Viral | 4 (15) | 0 | 4 (20) | 0.59 |
| Specific treatments | ||||
| Antifungal therapy | ||||
| - Curative L-AmB | 22 (85) | 6 (100) | 16 (80) | 0.59 |
| - Initial dosage of curative L-AmB | 5.0 [5.0–10.0] | 10.0 [5.0–10.0] | 5.0 [5.0–5.8] | 0.86 |
| - Maximal dosage of curative L-AmB | 10.0 [5.5–10.0] | 10.0 [8.1–10.0] | 10.0 [5.0–10.0] | 0.28 |
| - Dual therapy | 12 (46) | 4 (67) | 8 (40) | 0.50 |
| Curative surgery | 8 (31) | 2 (33) | 6 (30) | 1.00 |
| Outcomes | ||||
| Length of ICU stay (days) | 6.0 [2.3–10.8] | 4.0 [1.8–5.5] | 8.5 [2.8–17.5] | 0.18 |
| Length of hospital stay (days) | 28.5 [21.0–41.3] | 25.0 [15.0–37.0] | 29.0 [22.0–44.5] | 0.64 |
| End-of-life decision | 14 (54) | 3 (50) | 11 (90) | 1.00 |
ICU intensive care unit, L-AmB liposomal amphotericin B
aAccording to EORTC/MSG criteria